BRPI0909378A2 - métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b - Google Patents

métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b

Info

Publication number
BRPI0909378A2
BRPI0909378A2 BRPI0909378A BRPI0909378A BRPI0909378A2 BR PI0909378 A2 BRPI0909378 A2 BR PI0909378A2 BR PI0909378 A BRPI0909378 A BR PI0909378A BR PI0909378 A BRPI0909378 A BR PI0909378A BR PI0909378 A2 BRPI0909378 A2 BR PI0909378A2
Authority
BR
Brazil
Prior art keywords
antagonist
methods
treating disorders
nr2b subtype
selective nr2b
Prior art date
Application number
BRPI0909378A
Other languages
English (en)
Portuguese (pt)
Inventor
John Alan Kemp
Timothy Tasker
Original Assignee
Evotec Neurosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh filed Critical Evotec Neurosciences Gmbh
Publication of BRPI0909378A2 publication Critical patent/BRPI0909378A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0909378A 2008-03-27 2009-03-26 métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b BRPI0909378A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4008708P 2008-03-27 2008-03-27
PCT/EP2009/002241 WO2009118187A1 (en) 2008-03-27 2009-03-26 Methods for treating disorders using nmda nr2b-subtype selective antagonist

Publications (1)

Publication Number Publication Date
BRPI0909378A2 true BRPI0909378A2 (pt) 2015-10-06

Family

ID=40910288

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909378A BRPI0909378A2 (pt) 2008-03-27 2009-03-26 métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b

Country Status (14)

Country Link
US (1) US20110053951A1 (https=)
EP (1) EP2254580A1 (https=)
JP (3) JP2011516417A (https=)
KR (1) KR20100135847A (https=)
CN (1) CN101977606A (https=)
AU (1) AU2009228660B2 (https=)
BR (1) BRPI0909378A2 (https=)
CA (1) CA2719749A1 (https=)
IL (1) IL207835A0 (https=)
MX (1) MX2010009649A (https=)
NZ (1) NZ588698A (https=)
RU (1) RU2499598C2 (https=)
WO (1) WO2009118187A1 (https=)
ZA (1) ZA201006587B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140146217A (ko) 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
US11232319B2 (en) 2014-05-16 2022-01-25 The Trustees Of The University Of Pennsylvania Applications of automatic anatomy recognition in medical tomographic imagery based on fuzzy anatomy models
WO2016025917A1 (en) * 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
US10155727B2 (en) 2014-08-15 2018-12-18 Janssen Pharmaceuticals, Inc. Pyrazoles
KR102613179B1 (ko) 2015-06-01 2023-12-14 뤼겐 홀딩스 (케이맨) 리미티드 Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물
AU2016291158B2 (en) 2015-07-09 2020-04-30 Janssen Pharmaceutica Nv Substituted 4-azaindoles and their use as GluN2B receptor modulators
US10071988B2 (en) 2016-02-10 2018-09-11 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
US10732235B2 (en) * 2018-03-29 2020-08-04 Siemens Healthcare Gmbh Magnetic resonance method and apparatus using atlas-based masking for quantitative susceptibility mapping
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
CA3143103A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyridine carbamates and their use as glun2b receptor modulators
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
TW202112774A (zh) 2019-06-14 2021-04-01 比利時商健生藥品公司 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途
BR112021025141A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
AU2020293642A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
MX2021015511A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
CN114008052A (zh) 2019-06-14 2022-02-01 詹森药业有限公司 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1131031C (zh) * 1996-03-08 2003-12-17 弗·哈夫曼-拉罗切有限公司 作为nmda受体亚型阻断剂的4－苯基3，6－二氢－2h－吡啶基衍生物的应用
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
ATE257827T1 (de) * 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
ATE274494T1 (de) * 2000-04-20 2004-09-15 Hoffmann La Roche Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
US7022882B2 (en) * 2000-10-06 2006-04-04 The Regents Of The University Of California NMDA receptor channel blocker with neuroprotective activity
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
JP2009503520A (ja) * 2005-07-29 2009-01-29 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ベータアミロイド受容体及びその使用

Also Published As

Publication number Publication date
JP2011516417A (ja) 2011-05-26
CA2719749A1 (en) 2009-10-01
AU2009228660B2 (en) 2012-11-29
EP2254580A1 (en) 2010-12-01
CN101977606A (zh) 2011-02-16
RU2499598C2 (ru) 2013-11-27
AU2009228660A1 (en) 2009-10-01
MX2010009649A (es) 2010-12-17
US20110053951A1 (en) 2011-03-03
RU2010143864A (ru) 2012-05-10
WO2009118187A1 (en) 2009-10-01
KR20100135847A (ko) 2010-12-27
JP2016094430A (ja) 2016-05-26
JP2014098018A (ja) 2014-05-29
NZ588698A (en) 2012-06-29
IL207835A0 (en) 2010-12-30
ZA201006587B (en) 2012-02-29

Similar Documents

Publication Publication Date Title
BRPI0909378A2 (pt) métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b
CY2020036I1 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
BR112012025101A2 (pt) compostos antagonistas seletivos de receptor nk-3, composição farmacêutica e métodos para uso em distúrbios mediados por receptores nk-3
BRPI0912362A2 (pt) antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
IL248652A0 (en) Methods, compositions and devices for facilitating re-creation
IL212986A0 (en) Methods for treating eye disorders
BRPI0816845A2 (pt) Método aperfeiçoado para regeneração de absorvente
IL232222A0 (en) Methods for treating progressive multiple sclerosis
BRPI0922046A2 (pt) dispositivo de reprodução, método de reprodução e programa para reprodução estereoscópica
HRP20170246T1 (hr) Režim doziranja za selektivni agonist s1p1-receptora
FI20085171L (fi) Uudet selluloosajohdannaiset, menetelmä niiden valmistamiseksi sekä niiden käyttö
GB2467710B (en) Methods for treating social disorders
PT2361116T (pt) Aparelho de irradiação
BRPI0810071A2 (pt) Método para determinação do risco inicial de glaucoma
DK2244628T3 (da) Patientdata-sensorapparat
BRPI0914680A2 (pt) método para produção de dispositivos de distribuição
FI20085296L (fi) Menetelmä kipsin puhdistamiseksi
EP2331097A4 (en) METHOD FOR TREATING CNS DISEASES
DE102008010351B8 (de) Vorrichtung zum Pastillieren
BRPI0820406A2 (pt) Métodos para identificar aumento de antagonistas do receptor nmda
EP2387402A4 (en) METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS
ES2451508T8 (es) Proceso de acervación múltiple simultánea
BRPI0909659A2 (pt) tratamento para distúrbios relacionados oculares
BRPI0919599A2 (pt) aparelho para jogar jogos de azar
BRPI1014007A2 (pt) aparelho para seleção de suspensões de fibra.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: EVOTEC INTERNATIONAL GMBH (DE)

B25G Requested change of headquarter approved

Owner name: EVOTEC INTERNATIONAL GMBH (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]